Funding
Funding not disclosed
Founders
Product
Problem
Many viral infections, including COVID-19, can lead to long-term complications, or sequelae, for which effective treatments are lacking. Developing novel therapeutics and optimizing existing drugs for enhanced efficacy is a time-consuming process, delaying access to treatment for patients suffering from these complications.
Solution
Tackle Bio is a rapid drug development company focused on repurposing existing therapeutics to address life-threatening infectious diseases and their long-term complications. The company identifies promising drug candidates already approved for other indications and strategically repurposes them for rapid deployment to patients. Tackle Bio leverages its expertise in drug design and delivery to optimize these therapeutics, enhancing their efficacy against evolving medical challenges. Their pipeline is designed to provide solutions for patients experiencing both acute infections and post-infection sequelae.
Target Audience
The primary target audience includes patients suffering from viral infections and associated long-term complications, as well as healthcare providers seeking effective treatment options.
Features
- Focus on repurposing already-approved drugs for faster deployment.
- Expertise in drug design and delivery for optimized therapeutic efficacy.
- Pipeline targeting both acute infections and long-term complications.